2022
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook
Jaffe A, Taddei TH, Giannini EG, Ilagan‐Ying Y, Colombo M, Strazzabosco M. Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook. Liver International 2022, 42: 2607-2619. PMID: 36161463, PMCID: PMC10878125, DOI: 10.1111/liv.15432.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatocellular carcinomaLiver functionRisk factorsRelevant prognostic roleChronic hepatitis BResidual liver functionChronic liver diseaseManagement of patientsCare of patientsCommon risk factorsAppropriate surveillance strategiesSuccessful cancer treatmentC infectionCommon complicationHepatitis BMetabolic syndromePrognostic roleSignificant morbidityLongitudinal careCurrent careCancer recurrenceHCC managementLiver cancerHCC treatmentMetabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2022, 87-104. DOI: 10.1007/978-3-030-41683-6_51.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidence
2021
The Neglected Role of Bile Duct Epithelial Cells in NASH
Cadamuro M, Lasagni A, Sarcognato S, Guido M, Fabris R, Strazzabosco M, Strain AJ, Simioni P, Villa E, Fabris L. The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars In Liver Disease 2021, 42: 034-047. PMID: 34794182, DOI: 10.1055/s-0041-1739455.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseNonalcoholic steatohepatitisLiver diseaseInsulin resistancePrevalent liver diseaseBile duct epithelial cellsFatty liver diseaseSubset of patientsCommon pathogenetic mechanismDuct epithelial cellsMultiple biological effectsFibro-inflammationHepatic manifestationNAFLD patientsPortal fibrosisMetabolic syndromeBile ductDuctular reactionDisease progressionPathogenetic mechanismsLiver cancerMetabolic alterationsProgenitor cell compartmentEpithelial cellsDiseaseMetabolic Syndrome and Liver Cancer
Jaffe A, Strazzabosco M. Metabolic Syndrome and Liver Cancer. 2021, 1-19. DOI: 10.1007/978-3-030-37482-2_51-1.Peer-Reviewed Original ResearchHepatitis B virusNonalcoholic fatty liver diseaseMetabolic syndromeRisk factorsHepatocellular carcinomaLiver diseaseLiver cancerParticular hepatitis B virusIncidence of HCCAdvanced liver diseaseIndependent risk factorFatty liver diseaseType 2 diabetesUnderlying pathogenic mechanismsHepatic manifestationHCC incidenceViral hepatitisAdvanced fibrosisSignificant morbidityDiabetes leadsTime patientsB virusHCC riskHigh prevalenceLower incidence
2020
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression
Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Advances In Cancer Research 2020, 149: 321-387. PMID: 33579427, PMCID: PMC8800451, DOI: 10.1016/bs.acr.2020.10.005.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaMalignant progressionCommon primary liver cancerPrimary hepatic malignancyPrimary liver cancerStandard of careHigh mortality rateICCA developmentMalignant aggressivenessHepatic malignanciesHepatobiliary cancersTumor immunobiologyDesmoplastic stromaHepatocellular carcinomaLiver cancerMortality rateTherapy resistanceEpithelial cancersDeleterious roleCell originCancerReactive microenvironmentMicroenvironmental factorsProgressionManagement optionsCholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology & Hepatology 2020, 17: 557-588. PMID: 32606456, PMCID: PMC7447603, DOI: 10.1038/s41575-020-0310-z.Peer-Reviewed Original ResearchConceptsPrimary liver cancerExpert consensus statementCancer-related deathCell of originBiliary malignant tumorsStudy of CholangiocarcinomaGastrointestinal malignanciesHistological confirmationAvailable therapiesBiliary treeNew diagnostic toolsSilent presentationPatient outcomesConsensus statementMalignant tumorsLiver cancerCholangiocarcinomaAggressive natureAlarming mortalityCurrent diagnosisMolecular alterationsNon-invasive approachTumorsDiagnostic toolTherapy
2019
Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor
Milani E, Strazzabosco M, Fabris L, Cadamuro M. Molecular Pathogenesis: From Inflammation and Cholestasis to a Microenvironment-Driven Tumor. 2019, 167-182. DOI: 10.1007/978-3-030-22258-1_12.Peer-Reviewed Original ResearchTumor reactive stromaIntrahepatic cholangiocarcinomaReactive stromaTumor-infiltrating lymphocytesPrimary liver cancerTumor-associated macrophagesCancer-associated fibroblastsMalignant bile ductPro-invasive functionMain stromal cell typesBiliary lesionsProgenitor stem cellsBile ductChronic inflammationStromal cell typesPortal tractsTumor overgrowthLiver cancerPathogenetic sequenceMalignant transformationParacrine factorsTumor microenvironmentCholestasisOncogenic effectsInflammationIntrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wang X, Zhu AX. Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances. Hepatology 2019, 69: 1803-1815. PMID: 30251463, PMCID: PMC6433548, DOI: 10.1002/hep.30289.Peer-Reviewed Original ResearchConceptsIntrahepatic cholangiocarcinomaMortality rateFuture translational research opportunitiesNonalcoholic fatty liver diseasePlatelet-derived growth factor DPrimary hepatobiliary cancerFatty liver diseaseRecent clinical trialsTranslational research findingsHigh mortality rateCancer-associated myofibroblastsTranslational research opportunitiesGrowth factor DNonspecific cirrhosisLiver diseaseHepatobiliary cancersSerum biomarkersRisk factorsClinical trialsExtracellular vesicle biomarkersLiver cancerMedical conditionsAggressive cancerIntrahepatic cholangiocarcinogenesisTherapeutic implications
2017
Notch signaling and progenitor/ductular reaction in steatohepatitis
Morell CM, Fiorotto R, Meroni M, Raizner A, Torsello B, Cadamuro M, Spagnuolo G, Kaffe E, Sutti S, Albano E, Strazzabosco M. Notch signaling and progenitor/ductular reaction in steatohepatitis. PLOS ONE 2017, 12: e0187384. PMID: 29140985, PMCID: PMC5687773, DOI: 10.1371/journal.pone.0187384.Peer-Reviewed Original ResearchConceptsHepatic stellate cellsDuctular reactionRole of NotchMCD diet-fed miceMethionine-choline deficient (MCD) dietHepatic progenitor cell activationPrimary hepatic stellate cellsChronic liver diseaseDiet-fed miceTGF-β1 expressionAlternative therapeutic targetsTGF-β1 treatmentProgenitor cell activationNotch-1 activationLiver injuryMCD dietLiver diseaseFibrosis progressionNotch signalingDR responseLiver repairBSEP expressionHepatocyte cell lineLiver cancerAAV8-TBGMolecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expression 2017, 18: 31-50. PMID: 29070148, PMCID: PMC5860940, DOI: 10.3727/105221617x15088670121925.Peer-Reviewed Original ResearchConceptsMajority of patientsPrimary liver cancerCancer-related deathPotential prognostic relevanceDevelopment of metastasesPro-oncogenic pathwaysNovel druggable targetsMechanism of actionCholangiocarcinoma invasivenessMesenchymal-like phenotypeDevastating malignancyCurative treatmentMolecular mechanismsPoor prognosisPrognostic relevancePrimary tumorBiliary epitheliumLiver cancerUseful biomarkerAbnormal activationCCA cell invasionMost carcinomasCCA cellsTumor microenvironmentCholangiocarcinoma
2016
Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma
Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research 2016, 76: 4775-4784. PMID: 27328733, PMCID: PMC4987167, DOI: 10.1158/0008-5472.can-16-0188.Peer-Reviewed Original ResearchMeSH KeywordsActive Transport, Cell NucleusAnimalsAntineoplastic Agents, PhytogenicBile Duct NeoplasmsBlotting, WesternCell Line, TumorCell ProliferationCholangiocarcinomaHumansMiceMice, SCIDNeoplasm InvasivenessNeoplasm MetastasisPaclitaxelS100 Calcium-Binding Protein A4SumoylationXenograft Model Antitumor AssaysConceptsLow-dose paclitaxelNuclear S100A4Nuclear expressionSCID mouse xenograft modelPrimary liver cancerLocal tumor growthEGI-1 cellsCandidate therapeutic targetMouse xenograft modelMMP-9 secretionCholangiocarcinoma cell linesCholangiocarcinoma invasivenessLung disseminationMT1-MMP expressionCalcium binding proteinDismal prognosisRate of proliferationMetastatic spreadLiver cancerTumor massPaclitaxel treatmentXenograft modelTherapeutic targetTreatment opportunitiesMetastatic progression
2015
Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma?
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Epithelial-to-Mesenchymal Transition and Cancer Invasiveness: What Can We Learn from Cholangiocarcinoma? Journal Of Clinical Medicine 2015, 4: 2028-2041. PMID: 26703747, PMCID: PMC4693158, DOI: 10.3390/jcm4121958.Peer-Reviewed Original ResearchMesenchymal transitionAbundant stromal reactionEarly metastatic behaviorPrimary liver cancerEMT-like changesPotential therapeutic targetPro-invasive phenotypeSpecific disease mechanismsDismal prognosisBile ductChronic inflammationEMT biomarkersEpithelial malignanciesStromal reactionLiver cancerTumor stromaTherapeutic targetCholangiocarcinomaNew biomarkersTumor metastatizationMetastatic behaviorCCA cellsTherapeutic opportunitiesTumor microenvironmentStromal cells
2013
Notch signalling beyond liver development: Emerging concepts in liver repair and oncogenesis
Morell CM, Fiorotto R, Fabris L, Strazzabosco M. Notch signalling beyond liver development: Emerging concepts in liver repair and oncogenesis. Clinics And Research In Hepatology And Gastroenterology 2013, 37: 447-454. PMID: 23806629, DOI: 10.1016/j.clinre.2013.05.008.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnimalsBile Duct NeoplasmsBiliary TractCalcium-Binding ProteinsCarcinogenesisCarcinoma, HepatocellularCholangiocarcinomaHepatocytesHumansIntercellular Signaling Peptides and ProteinsJagged-1 ProteinLiverLiver NeoplasmsLiver RegenerationMembrane ProteinsReceptor Cross-TalkReceptors, NotchSerrate-Jagged ProteinsSignal Transduction